Rasey J S, Krohn K A, Menard T W, Spence A M
Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1487-90. doi: 10.1016/0360-3016(86)90200-2.
The organ level biodistribution and tumor radioprotective properties of three drugs have been compared: WR-2721 (NSC 296961), WR-3689 (NSC 327729), and WR-77913 (NSC 318809). The three drugs have similar distribution patterns in normal mouse tissues. At 30 minutes after intraperitoneal injection, highest levels of 35S from radiolabeled protector are found in kidney and submandibular salivary gland, with lowest levels in brain and moderately low values in tumor and skin. Three of four tumors examined take up less WR-3689 than the other two protectors. For the three protectors, the dose modifying factors for the RIF-1 tumor irradiated in vivo and assayed in vitro are 1.5-1.7, but do not vary as predicted by differential uptake of drug into this neoplasm. In RIF-1, WR-3689 is taken up most avidly, but the three drugs tend to be equally protective.
WR-2721(NSC 296961)、WR-3689(NSC 327729)和WR-77913(NSC 318809)。这三种药物在正常小鼠组织中的分布模式相似。腹腔注射后30分钟,放射性标记保护剂中的35S在肾脏和下颌下唾液腺中的含量最高,在脑内含量最低,在肿瘤和皮肤中的含量适中偏低。所检查的四个肿瘤中有三个摄取的WR-3689比其他两种保护剂少。对于这三种保护剂,体内照射并体外测定的RIF-1肿瘤的剂量修正因子为1.5-1.7,但并不随药物对该肿瘤的差异摄取所预测的那样变化。在RIF-1肿瘤中,WR-3689的摄取最为活跃,但这三种药物的防护作用趋于相同。